Remarkable Response to Rituximab in a 72-Year-Old Patient with Refractory Non-Hodgkin's Lymphoma and Marrow Aplasia

G. Egerer Department of Internal Medicine V, Hematology, Oncology and Rheumatology, University of Heidelberg, Hospitalstr. 3, 69115, Heidelberg, Germany

K. Sauerland Department of Internal Medicine V, Hematology, Oncology and Rheumatology, University of Heidelberg, Hospitalstr. 3, 69115, Heidelberg, Germany

A. D. Ho Department of Internal Medicine V, Hematology, Oncology and Rheumatology, University of Heidelberg, Hospitalstr. 3, 69115, Heidelberg, Germany

Abstract

The chimeric human mouse antibody rituximab represents a substantial advance over the use of unmodified murine antibodies. Multicenter trials showed that rituximab induced remission in 48% of 166 relapsed lymphoma patients with minimal toxicity. Thus, the antibody might play a role in patients who cannot tolerate chemotherapy because of marrow aplasia. We observed a continuous complete remission induced by rituximab alone in a 72 year old patients with refractory and progressive high-grade non-Hodgkin's lymphoma (NHL) in the phase of chemotherapy induced marrow aplasia.

Key Words:

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Remarkable Response to Rituximab in a 72-Year-Old Patient with Refractory Non-Hodgkin's Lymphoma and Marrow Aplasia

Information for

Open access

Opportunities

Help and information

Remarkable Response to Rituximab in a 72-Year-Old Patient with Refractory Non-Hodgkin's Lymphoma and Marrow Aplasia

Abstract

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature